Patients should be informed that neutropenia will be monitored via blood draws prior to each T-DXd dose and as clinically indicated.9 They should be advised that the T-DXd dose could be held or reduced, and/or supportive treatment with a granulocyte colony-stimulating factor could be added if neutropenia develops. This evidence concerns the gene CSF3 and neutropenia.